Sluggish healthcare sales drag down Philips overall figures, but the company is eying a comeback for the 2nd half of the year.
Philips Healthcare (NYSE:PHG) had a tough 2nd quarter with a shutdown of a manufacturing facility in Cleveland taking some of the wind out of the sales for the entire company.
AtriCure gets some Wall Street love after again boosting its full-year expectations on the back of a 30% boost in revenues in its 2nd quarter.
Ohio-based AtriCure (NSDQ:ATRC) gained a few points today as investors reacted to new of the company's Q2 financial report.
Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.
C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.
Covidien's fiscal 3rd-quarter sales come in dead even with expectations on Wall Street as its earnings top analysts' consensus estimate.
Zimmer Holdings misses 2nd-quarter sales expectations, just meets Wall Street's earnings forecast and cuts its 2014 guidance, sending share prices down this morning.
Zimmer (NYSE:ZMH) shares are down this morning after the orthopedic device maker reported disappointing 2nd-quarter results and cut its outlook for the rest of the year.
Boston Scientific beats Wall Street's expectations and its own forecasts for 2nd-quarter sales and earnings, with strong performances from its core implantable cardiac defibrillator and drug-eluting stent businesses.
ConMed names former Stryker CFO Curt Hartman interim CEO and lowers its outlook for the rest of the year.
Surgical device maker ConMed (NSDQ:CNMD) took a major hit on Wall Street today after announcing some turnover at the top and lowering its financial outlook for the rest of the year.